Eduardo Martinez-Montes

Antonio Eduardo Arce

- Co-Diagnostics, Inc. announced the pricing of a registered direct offering to raise approximately **$7.0 million** in gross proceeds.  **[1692415_0001493152-25-020100_ex99-1.htm:0]** **[1692415_0001493152-25-020100_form8-k.htm:1]** 
- The offering involves the sale of **12,727,272 shares of common stock** (or pre-funded warrants in lieu thereof) at an offering price of **$0.55 per share**.  **[1692415_0001493152-25-020100_ex99-1.htm:0]** 
- The company intends to use the proceeds from the offering for **working capital and general corporate purposes**.  **[1692415_0001493152-25-020100_ex99-1.htm:0]** **[1692415_0001493152-25-020100_form8-k.htm:1]** 
- The offering is expected to close on or about **October 29, 2025**.  **[1692415_0001493152-25-020100_ex99-1.htm:0]** **[1692415_0001493152-25-020100_form8-k.htm:1]**

Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering

- Co-Diagnostics, Inc. (CODX) announced the **closing** of its previously announced offering on **October 29, 2025**.  **[1692415_20251029LA10291:0]** 
- The offering involved **12,727,272 shares** of common stock (or pre-funded warrants) at an offering price of **$0.55 per share**.  **[1692415_20251029LA10291:0]** 
- The company received approximately **$7.0 million** in gross proceeds from the offering.  **[1692415_20251029LA10291:0]** 
- Proceeds from the offering are intended for **working capital and general corporate purposes**.  **[1692415_20251029LA10291:0]**

Co-Diagnostics Announces Closing of $7.0 Million Stock Offering

- Co-Diagnostics, Inc. has entered into a securities purchase agreement for a registered direct offering.  **[1692415_20251028LA08597:0]** 
- The offering involves the purchase and sale of **12,727,272 shares of common stock** (or pre-funded warrants) at an offering price of **$0.55 per share**.  **[1692415_20251028LA08597:0]** 
- The gross proceeds to the company from the offering are estimated to be approximately **$7.0 million**.  **[1692415_20251028LA08597:0]** 
- The company intends to use the proceeds for working capital and general corporate purposes.  **[1692415_20251028LA08597:0]** 
- The offering is expected to close on or about **October 29, 2025**.  **[1692415_20251028LA08597:0]**

Co-Diagnostics Announces Pricing of Registered Direct Offering

- Co-Diagnostics, Inc. has entered into a definitive agreement with Arabian Eagle Manufacturing to form **CoMira Diagnostics**, a joint venture in the Kingdom of Saudi Arabia.  **[1692415_20251027LA06960:0]** 
- The new JV will be engaged in the **manufacturing and distribution** of Co-Dx™ PCR platform and other Co-Dx intellectual property across Saudi Arabia and **18 other Middle East and North Africa (MENA) countries**.  **[1692415_20251027LA06960:0]** 
- Co-Diagnostics will provide CoMira an **exclusive license** to use, manufacture, and commercialize its licensed IP, including the upcoming Co-Dx PCR platform and existing lab-based PCR diagnostic products.  **[1692415_20251027LA06960:1]** 
- This partnership aligns with **Saudi Vision 2030**, supporting technology localization, industrial diversification, and healthcare innovation.  **[1692415_20251027LA06960:0]**

Co-Diagnostics Forms Joint Venture CoMira Diagnostics in Saudi Arabia

- **Co-Diagnostics (CODX) announced the development of a proprietary sample preparation instrument** designed to streamline and simplify the workflow for its point-of-care (PoC) PCR Mycobacterium Tuberculosis (MTB) Test.  **[1692415_20251016LA99495:0]** 
- This instrument is engineered to facilitate **decentralized PCR testing in nearly 30,000 primary health centers across India**, supporting both sputum and novel tongue swab sample collection.  **[1692415_20251016LA99495:0]** 
- The device features **low-cost, user-friendly operation** with minimal training and includes a built-in safety feature to inactivate live organisms.  **[1692415_20251016LA99495:0]** 
- **Systronics** is anticipated to be the manufacturing partner, which will allow the device to qualify for the **"Make in India" initiative**.  **[1692415_20251016LA99495:0]** 
- Clinical evaluations for the MTB test are **expected to begin in India before year-end**.  **[1692415_20251016LA99495:0]**

Co-Diagnostics Announces Development of Proprietary Sample Preparation Instrument

- Co-Diagnostics (CODX) presented its **CODX PCR Pro platform**, a compact, low-cost, smartphone-operated device designed for real-time PCR diagnostics, capable of delivering results in approximately **30 minutes** using its proprietary **CoPrimers technology** for multiplex testing.  **[1692415_2162801_1]** **[1692415_2162801_2]** **[1692415_2162801_3]** 
- The company is targeting significant market opportunities in the U.S., including physicians, urgent care facilities, pharmacies, skilled nursing facilities, and the home market.  **[1692415_2162801_3]** 
- Co-Diagnostics has a joint venture in India, established in **2017**, which has **15 authorized tests** with the CDSCO and recently opened a new oligonucleotide manufacturing facility. The focus in India includes **tuberculosis (TB)** and **human papillomavirus (HPV)** tests, with the CODX PCR Pro device costing **less than $1,000** compared to higher-priced alternatives.  **[1692415_2162801_4]** 
- The CODX PCR platform is currently undergoing FDA regulatory review and is not yet available for sale. The company's regulatory strategy includes seeking FDA clearance for a multiplex flu A/B/COVID-19/RSV test, as well as pursuing regulatory authority in India, South Africa, and Saudi Arabia.  **[1692415_2162801_1]** **[1692415_2162801_4]** **[1692415_2162801_5]**

Co-Diagnostics Showcases CODX PCR Pro Platform and Global Market Strategy

- Co-Diagnostics, Inc. (CODX) announced the **closing** of its registered direct offering on **September 18, 2025**.  **[1692415_20250918LA77466:0]** 
- The offering involved the sale of **9,619,000 shares** of common stock at an offering price of **$0.40 per share**.  **[1692415_20250918LA77466:0]** 
- The company received approximately **$3.8 million** in gross proceeds from the offering.  **[1692415_20250918LA77466:0]** 
- The proceeds are intended for **working capital and general corporate purposes**.  **[1692415_20250918LA77466:0]**

Co-Diagnostics Closes Registered Direct Offering

- Co-Diagnostics, Inc. priced a registered direct offering of **9,619,000 shares** of common stock at **$0.40 per share**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The offering is expected to generate approximately **$3.8 million** in gross proceeds for the company.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The company intends to use the proceeds for **working capital and general corporate purposes**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- The offering is anticipated to close on or about **September 18, 2025**.  **[1692415_0001493152-25-013981_ex99-1.htm:0]** **[1692415_0001493152-25-013981_form8-k.htm:1]** 
- Co-Diagnostics has agreed to restrictions on issuing common stock or equivalents for **30 days** following the closing and has granted participation rights to investors for subsequent financing within 12 months.  **[1692415_0001493152-25-013981_form8-k.htm:1]** **[1692415_0001493152-25-013981_ex10-1.htm:29]**

Co-Diagnostics, Inc. Announces Pricing of $3.8 Million Registered Direct Offering

- Co-Diagnostics, Inc. has entered into a securities purchase agreement for a registered direct offering of common stock.  **[1692415_20250917LA75875:0]** 
- The offering involves the sale of **9,619,000 shares** of common stock at an offering price of **$0.40 per share**.  **[1692415_20250917LA75875:0]** 
- The gross proceeds are estimated to be approximately **$3.8 million**, which the Company intends to use for **working capital and general corporate purposes**.  **[1692415_20250917LA75875:0]** 
- The offering is expected to close **on or about September 18, 2025**.  **[1692415_20250917LA75875:0]**

Co-Diagnostics Announces Pricing of Common Stock Offering

- **Co-Diagnostics, Inc.** (CODX) has signed a strategic **Memorandum of Understanding (MOU)** with a regional manufacturing and distribution company in the **Kingdom of Saudi Arabia (KSA)** to explore a joint venture.  **[1692415_20250916LA74199:0]** 
- This joint venture aims to develop, manufacture, and distribute **Co-Dx intellectual property**, including the upcoming **Co-Dx™ PCR platform**, throughout the **Middle East and North Africa (MENA)** region.  **[1692415_20250916LA74199:0]** 
- The KSA partner will provide **local operational support, infrastructure, personnel, and regulatory expertise**, with the JV's mission aligning with **KSA's Vision 2030** to potentially qualify for government incentives.  **[1692415_20250916LA74199:0]**